FDA Inspection 1216225 — Reproductive Medicine Institute
The FDA completed an inspection of Reproductive Medicine Institute on Aug 16, 2023 in Chicago, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 16, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Chicago, IL (United States)